TargaZyme is a clinical-stage biotechnology company based in San Diego, CA and focused on the research and development of disruptive and novel, off-the-shelf T-Cell products that are aimed at improving the efficacy of T-cell therapies by delivering more T-cells to to tumor sites from the vasculature, increasing the percentage of T-cells in the tumor micro-environment that express FASL, Granzyme B & Perforin, increasing the synapse formation between the T-cells and tumors, enabling increased  intra-tumor penetration,  and improving the cytoxicity of T-cells for increased cancer tumor killing. TargaZyme’s technologies/products were founded by a world-renowned physician scientists:

Rodger McEver MD: A renowned glycobiologist and hematologist, Dr. Rodger McEver also serves as Oklahoma Medical Research Foundation’s Chief Scientific Officer. Dr. McEver also co-founded a pair of biotechnology companies: Selexys Pharmaceuticals Corp., which was acquired by Novartis, and Tetherex Pharmaceuticals. Lijun Xia, M.D., PhD: At Oklahoma Medical Research Foundation (OMRF), Lijun Xia, M.D., Ph.D., has spent two decades studying O-glycans, a form of sugar that the body produces and that comprises nearly 80 percent of a thick mucous layer inside the colon and the gastrointestinal tract. Dr. Xia was a practicing hematologist/oncologist and currently chairs OMRF’s Cardiovascular Department.

Gheath Al-Atrash MD, PhD: Dr. Gheath Al-Atrash is the medical/scientific founder of TZ 102 T-cell therapy and is a physician-scientist at The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy.

TargaZyme is a pioneer of cellular therapy and has accumulated the experience of advancing a portfolio of proprietary cell-enabling enzyme products, at scale, through Phase-2 clinical trials and a Phase 3 Special Protocol Assessment (SPA) award from the FDA, with multiple FDA orphan-drug designations. The company has over 40 worldwide-awarded patents and another 35 patent applications pending. TargaZyme has partnerships and collaborations with Kyowa Hakko Kirin, Aragen Bioscience, AVID Biotechnologies, and Thermo-Fisher in addition to various medical research institutions, including MD Anderson Cancer Center, Oklahoma Medical Research Foundation, Harvard Medical Center, University of Pennsylvania Medical Center, Cleveland Clinic, Scripps Hospitals, Case Western/University Hospitals, Fred Hutchinson Cancer Research Center, Moore’s Cancer Center, UCSF,UCLA Medical Cancer Center, Northwestern University Medical Center, Sanford-Burnham Medical Research Institute and Indiana University.